Pancreatic Cancer Research

ResearcherEmory UniversityActive in the last 2 years

Matthew R. Farren

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5510-8869; OpenAlex author ID A5036794959. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
40
Papers, trials and grants by year

2015: 1 paper · 2016: 2 papers · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 10

  1. Correction: Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-26-0614↗
  2. Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-19-0911↗
  3. Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy. Co-author DOI 10.1172/jci.insight.130362↗
  4. Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer. Co-author DOI 10.1016/j.pan.2018.11.002↗
  5. Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naïve pancreatic cancer patients. Co-author DOI 10.1002/jcsm.12251↗
  6. Inhibiting heat shock protein 90 and the ubiquitin-proteasome pathway impairs metabolic homeostasis and leads to cell death in human pancreatic cancer cells. Co-author DOI 10.1002/cncr.30944↗
  7. Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment. Co-author DOI 10.1158/0008-5472.can-16-1986↗
  8. Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. First author DOI 10.1038/mt.2016.66↗
  9. Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-15-1732↗
  10. Immunological predictors of overall survival in treatment naïve metastatic pancreatic cancer patients Co-author DOI 10.1186/2051-1426-3-s2-p85↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gregory B. Lesinski · 10 shared papers, 2015–2026 · strength 0.86
  2. Bassel F. El‐Rayes · 5 shared papers, 2016–2026 · strength 0.57
  3. Juan Manuel Sarmiento · 3 shared papers, 2020–2026 · strength 0.46
  4. Michael B. Ware · 3 shared papers, 2020–2026 · strength 0.46
  5. Shishir Kumar Maithel · 3 shared papers, 2020–2026 · strength 0.46
  6. Ganji Purnachandra Nagaraju · 3 shared papers, 2017–2026 · strength 0.43
  7. Thomas A. Mace · 5 shared papers, 2015–2019 · strength 0.27
  8. Tanios Bekaii‐Saab · 5 shared papers, 2015–2019 · strength 0.27
  9. Yuchen Zhang · 1 shared paper, 2026 · strength 0.25
  10. Daniel H. Ahn · 4 shared papers, 2015–2019 · strength 0.22
  11. Anne M. Noonan · 4 shared papers, 2015–2019 · strength 0.22
  12. Walid Labib Shaib · 2 shared papers, 2017–2020 · strength 0.16
  13. Christina Sing-Ying Wu · 3 shared papers, 2015–2016 · strength 0.14
  14. Erin E. Talbert · 2 shared papers, 2018–2019 · strength 0.14
  15. Mitchell L. Ramsey · 2 shared papers, 2018–2019 · strength 0.14
  16. Denis C. Guttridge D · 2 shared papers, 2018–2019 · strength 0.14
  17. Timothy Michael Pawlik · 2 shared papers, 2018–2019 · strength 0.14
  18. Mary E. Dillhoff · 2 shared papers, 2018–2019 · strength 0.14
  19. Phil A. Hart · 2 shared papers, 2018–2019 · strength 0.14
  20. Zobeida Cruz‐Monserrate · 2 shared papers, 2017–2019 · strength 0.12
  21. Yuchen Zhang · 1 shared paper, 2021 · strength 0.11
  22. David A. Kooby · 1 shared paper, 2020 · strength 0.09
  23. Pretesh R Patel · 1 shared paper, 2020 · strength 0.09
  24. Alyssa M. Krasinskas · 1 shared paper, 2020 · strength 0.09
  25. Darwin Lewis Conwell · 1 shared paper, 2019 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.